Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Fractional Flow Reserve
FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial
Posted inCardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial

Posted by MedXY By MedXY 02/04/2026
The 11-year FAME 2 trial results confirm that FFR-guided PCI significantly improves outcomes for stable CAD patients with functionally significant lesions, primarily by reducing urgent revascularizations, reinforcing the importance of physiological assessment in revascularization decisions.
Read More
Validating the 0.80 FFR Threshold: Long-Term Outcomes from the NOTION-3 Trial in TAVR Patients
Posted inCardiology news

Validating the 0.80 FFR Threshold: Long-Term Outcomes from the NOTION-3 Trial in TAVR Patients

Posted by MedXY By MedXY 01/17/2026
The NOTION-3 trial demonstrates that FFR-guided revascularization significantly reduces cardiovascular risks in TAVR patients with coronary artery disease, validating the 0.80 threshold for clinical decision-making.
Read More
Coronary Collaterals Attenuate Chest Pain in Stable Angina: Evidence From an Invasive Placebo‑Controlled N‑of‑1 Study
Posted inCardiology news

Coronary Collaterals Attenuate Chest Pain in Stable Angina: Evidence From an Invasive Placebo‑Controlled N‑of‑1 Study

Posted by MedXY By MedXY 12/02/2025
An invasive, placebo‑controlled n‑of‑1 study shows that greater coronary collateral flow is associated with higher ischemic burden but lower pain intensity during controlled coronary occlusion, helping explain the weak correlation between stenosis severity and angina symptoms.
Read More
FFR-Guided Complete Revascularization Enhances Outcomes in NSTEMI with Multivessel Disease: Insights from the SLIM Trial
Posted inCardiology Clinical Updates Radiology Specialties

FFR-Guided Complete Revascularization Enhances Outcomes in NSTEMI with Multivessel Disease: Insights from the SLIM Trial

Posted by MedXY By MedXY 09/01/2025
The SLIM trial demonstrates that fractional flow reserve–guided complete revascularization during the index procedure significantly reduces major adverse events at one year in patients with NSTEMI and multivessel disease, primarily by lowering repeat revascularizations.
Read More
Long-Term Comparative Outcomes of FFR vs IVUS-Guided PCI in Intermediate Coronary Stenosis: Insights from the FLAVOUR Trial Extended Follow-Up
Posted inCardiology Radiology Specialties

Long-Term Comparative Outcomes of FFR vs IVUS-Guided PCI in Intermediate Coronary Stenosis: Insights from the FLAVOUR Trial Extended Follow-Up

Posted by MedXY By MedXY 08/22/2025
The FLAVOUR trial's extended 6.3-year follow-up shows equivalent long-term outcomes for FFR- and IVUS-guided PCI strategies in intermediate coronary stenosis, with FFR associated with fewer total PCIs but slight increases in late revascularization.
Read More
  • Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial
  • AI-Enabled Stethoscopes in Primary Care: Why Implementation Science Matters More Than Algorithm Accuracy
  • Minocycline Significantly Improves Functional Recovery in Acute Ischaemic Stroke: Evidence from the EMPHASIS Trial
  • Long-term Impact of Adjunctive Ultrasonography on Advanced Breast Cancer: A Secondary Analysis of the J-START Trial
  • Adjunctive Ultrasonography Reduces Advanced Breast Cancer Risk in Women Aged 40-49: Long-Term Evidence from J-START
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in